You are viewing a free preview of this lesson.
Subscribe to unlock all 10 lessons in this course and every other course on LearningBro.
Biological models explain addiction in terms of brain systems, neurochemistry and genetic predisposition, treating dependence as a consequence of the way addictive substances and behaviours act on the brain's natural reward circuitry. Their central claim is that addiction is, in large part, a brain condition: repeated activation of the reward system by an addictive substance or behaviour produces lasting neuroadaptations that drive craving, tolerance and withdrawal, and that genetic differences make some people more vulnerable than others. For the AQA specification, the focus falls on the brain's reward system and the mesolimbic dopamine pathway, the action of specific substances (the desensitisation account of nicotine addiction and the role of dopamine/reward in gambling), genetic vulnerability, and the neural basis of tolerance and withdrawal. These models are important because they explain why addiction is so resistant to willpower and why several effective treatments are pharmacological. The topic is treated clinically and objectively, in the standard register of A-Level teaching.
Key Definition: The mesolimbic dopamine pathway is the brain's principal reward circuit, running from the ventral tegmental area (VTA) in the midbrain to the nucleus accumbens, with projections to the prefrontal cortex. It is activated by naturally rewarding experiences and is powerfully engaged ("hijacked") by addictive substances and behaviours.
This lesson addresses the following points from the AQA A-Level Psychology (7182) specification, Paper 3, Section D — Addiction:
It develops the brain's reward system and the mesolimbic dopamine pathway, the desensitisation account of nicotine addiction, the role of dopamine and reward in gambling, genetic vulnerability, and the neuroadaptational basis of tolerance and withdrawal, preparing you to describe (AO1) and evaluate (AO3) the biological approach. Questions are usually split AO1/AO3 only, with no AO2 unless a scenario stem is provided — this lesson flags that distinction. The content builds directly on the descriptive features set out in the "describing addiction" lesson and contrasts with the learning and cognitive models that follow.
Naturally rewarding experiences — eating when hungry, drinking when thirsty, social bonding, sex — activate the mesolimbic dopamine pathway:
This circuit is evolutionarily ancient: it evolved to reinforce survival- and reproduction-promoting behaviours by making them feel rewarding, so that they are repeated. Dopamine in this system is best understood not simply as a "pleasure chemical" but as a signal of reward and incentive salience — it tags experiences (and the cues that predict them) as important and worth pursuing, which is why it is so central to motivation and to addiction.
A useful refinement, drawn from the incentive-salience account, is the distinction between "liking" (the actual pleasure obtained from a reward) and "wanting" (the dopamine-driven motivation to obtain it). In addiction these can come apart: as tolerance develops, the liking (pleasure) often fades while the wanting (craving, compulsive seeking) becomes ever stronger, because the reward system has become sensitised to the substance and its cues. This helps explain the otherwise puzzling clinical observation that long-term addicts may report getting little real enjoyment from the substance yet feel an overwhelming compulsion to take it. Alongside this, repeated reward-pathway activation is associated with reduced regulatory control by the prefrontal cortex, which normally weighs long-term consequences and inhibits impulsive action; as prefrontal control weakens relative to a sensitised reward and craving system, the capacity to resist use is undermined — a neural picture of the "loss of control" that defines addiction.
Addictive drugs act on this circuit to produce dopamine release in the nucleus accumbens that is larger and more reliable than that produced by natural rewards. Because the dopamine signal also tags the cues that predict reward, the people, places and rituals surrounding substance use acquire strong incentive salience, helping to explain the craving and cue-driven relapse described in the learning model. The repeated, outsized activation of the reward pathway is what the brain "learns" to seek, and it sets in motion the neuroadaptations underlying tolerance and withdrawal.
graph LR
A[Substance or Reward] --> B[VTA Activated]
B --> C[Dopamine Released into Nucleus Accumbens]
C --> D[Reward / Incentive Salience Signalled]
D --> E[Prefrontal Cortex Encodes Memory and Cues]
E --> F[Craving and Seeking Behaviour]
F --> A
Nicotine illustrates the biological model in detail. Inhaled nicotine is absorbed rapidly and reaches the brain within seconds, where it binds to nicotinic acetylcholine receptors (nAChRs) on dopamine neurons in the VTA, stimulating dopamine release in the nucleus accumbens and producing the mild reinforcement (alertness, relaxation, a brief lift) that smokers experience.
The desensitisation hypothesis explains how this leads to dependence and to the characteristic pattern of smoking. When nicotine binds repeatedly, the nicotinic receptors first become activated and then desensitised — temporarily unresponsive — and the brain compensates by upregulating (increasing) the number of nicotinic receptors. This produces two consequences that drive addiction:
graph TD
A[Nicotine binds nicotinic receptors in VTA] --> B[Dopamine released: reinforcement]
B --> C[Repeated use: receptors desensitise]
C --> D[Brain upregulates receptor numbers]
D --> E[Tolerance and craving between cigarettes]
E --> F[Next cigarette restimulates receptors / relieves craving]
F --> A
This account elegantly explains why smokers settle into frequent, regular dosing throughout the day: smoking comes to be driven less by pleasure than by the need to keep desensitised, upregulated receptors topped up and to avoid the aversive between-cigarette state — a biological version of the shift from positive to negative reinforcement.
Gambling shows that the biological model is not confined to ingested substances. Although no chemical enters the body, gambling activates the same mesolimbic dopamine reward pathway as drug rewards, which is central to why it is now grouped with the substance addictions. Several features are important:
These mechanisms explain why gambling can produce craving, escalation (a tolerance-like need to bet more for the same excitement) and compulsive continuation, paralleling the features of substance addiction at the level of the reward system.
The role of uncertainty deserves emphasis, because it is what distinguishes gambling from an ordinary reward. In gambling, the reward itself is uncertain, and the dopamine system responds powerfully to this uncertainty — anticipation under unpredictable conditions produces sustained dopamine signalling. Modern gambling products exploit this: features such as frequent near misses, rapid play and the "almost won" structure of slot machines are, in effect, engineered to maximise reward-pathway activation. This biological account also dovetails with the neuroadaptation story below: with heavy gambling, the reward system may become dysregulated in much the same way as with drugs, so that ordinary rewards feel flat and only the intense, uncertain reward of gambling produces a strong signal — a reward-deficiency-like pattern that helps explain the escalation and preoccupation seen in gambling disorder.
Key Definition: Intermittent reinforcement is a partial reinforcement schedule in which rewards are delivered unpredictably. It produces highly persistent, extinction-resistant behaviour and is central to the reward-based account of gambling addiction.
Biological models hold that genetic differences make some people more vulnerable to addiction, consistent with the heritability evidence introduced in the "describing addiction" lesson.
The proposed reward-deficiency mechanism connects genetics directly to the reward-system account: if an individual inherits a dopamine system that delivers a weaker everyday reward signal, ordinary pleasures may feel muted, and substances or behaviours that produce an unusually strong dopamine surge become correspondingly more attractive as a way of reaching a "normal" level of reward. Genes may also act more indirectly, by shaping temperament (impulsivity, sensation-seeking) and metabolism (how quickly a substance such as nicotine is broken down, which affects dosing patterns) — so genetic vulnerability is rarely specific to one drug but instead tilts the whole reward–temperament system towards dependence once exposure occurs.
Crucially, addiction is polygenic — many genes each contribute a small effect — and no single "addiction gene" exists. Genetic findings for specific candidate genes such as DRD2 have been inconsistent across studies, so genes are best described as conferring a predisposition that interacts with environment rather than determining addiction. The interaction is genuinely two-way: genetic vulnerability raises the impact of environmental exposure (a gene–environment interaction), and predisposing traits may also lead individuals to seek out high-risk environments (a gene–environment correlation), which is one reason simple "how much is genetic?" questions are harder to answer than heritability figures suggest.
The biological model explains tolerance and withdrawal through neuroadaptation — the brain's adjustment to the persistent presence of a substance.
With repeated exposure, the brain attempts to restore balance by:
Because the brain is now adapted to the drug, the individual needs more of it to achieve the original effect (tolerance), and when the drug is removed the adapted brain is left unbalanced, producing the aversive withdrawal state. A useful theoretical framing is the idea of opposing processes: an initial drug-induced positive state (the A-process: euphoria, relaxation) is automatically countered by an opposing restorative state (the B-process: discomfort, craving). With repeated use the A-process weakens (tolerance) while the B-process grows stronger and longer-lasting, so the individual increasingly uses the drug to suppress the B-process (avoid withdrawal) rather than to enjoy the A-process — the neural basis of the shift from positive to negative reinforcement.
| Stage | A-Process (drug-induced pleasure) | B-Process (opposing withdrawal state) | Dominant motivation |
|---|---|---|---|
| Early use | Strong | Weak, short-lasting | Positive reinforcement (seeking the "high") |
| Chronic use | Weak (tolerance) | Strong, long-lasting | Negative reinforcement (avoiding withdrawal) |
Key Definition: Neuroadaptation is the process by which the brain adjusts to the sustained presence of a substance by altering neurotransmitter production, receptor density or metabolic activity. It is the neural basis of both tolerance and withdrawal.
Applying this to the AQA examples ties the model together. In nicotine addiction, neuroadaptation takes the specific form of nicotinic-receptor desensitisation and upregulation: tolerance and the between-cigarette craving state are two faces of the same adaptation, and the A-process/B-process shift explains why long-term smokers smoke largely to feel normal rather than to feel good. In gambling, although there is no ingested drug, an analogous reward-system dysregulation is proposed — heavy gambling may blunt responses to ordinary rewards, so that the gambler escalates (a tolerance-like effect) and experiences restlessness and craving when stopping (a withdrawal-like B-process). Seeing the same neuroadaptational logic in a substance and a behaviour is precisely what gives the biological model its claim to explain addiction as a unified category.
Subscribe to continue reading
Get full access to this lesson and all 10 lessons in this course.